| __timestamp | Bristol-Myers Squibb Company | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 675200000 |
| Thursday, January 1, 2015 | 5001000000 | 771800000 |
| Friday, January 1, 2016 | 5002000000 | 1205500000 |
| Sunday, January 1, 2017 | 4849000000 | 1146500000 |
| Monday, January 1, 2018 | 4551000000 | 1125800000 |
| Tuesday, January 1, 2019 | 4871000000 | 1166100000 |
| Wednesday, January 1, 2020 | 7661000000 | 1175500000 |
| Friday, January 1, 2021 | 7690000000 | 1111400000 |
| Saturday, January 1, 2022 | 7814000000 | 1210100000 |
| Sunday, January 1, 2023 | 7772000000 | 1274600000 |
| Monday, January 1, 2024 | 8414000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and Perrigo Company plc from 2014 to 2023. Over this period, Bristol-Myers Squibb consistently outspent Perrigo, with its SG&A expenses peaking in 2022 at approximately 7.8 billion dollars, a 37% increase from its 2014 figures. In contrast, Perrigo's expenses showed a steadier growth, reaching around 1.3 billion dollars in 2023, marking an 89% rise since 2014. This disparity highlights Bristol-Myers Squibb's aggressive investment in administrative and sales strategies, while Perrigo maintains a more conservative approach. Such insights are invaluable for investors and stakeholders aiming to gauge the strategic priorities and operational efficiencies of these pharmaceutical giants.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.
Viatris Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Perrigo Company plc or Xencor, Inc.: Who Manages SG&A Costs Better?